Bortezomib Modified Aug BFM Backbone in New Dxd T-ALL & T-LLy

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

November 22, 2017

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica

    Trial Phone: 321.841.3837

  • IRB No: AALL1231

    Principal Investigator: Vincent F. Giusti, MD

    Sub Investigators: AguilarBonilla, Ana MD; Eslin, Don MD; Gray, Rachel PA-C; Kelly, Susan MD; Martin, Rebecca, ARNP; Pope, Michele ARNP; Smith, Amy MD; Story, Allison ARNP; Sullivan, Kelly ARNP; Sutphin, Robert MD; Wieber, Laura ARNP; Levy, Alejandro MD

    Phase: Drug: Phase III

    Age Group: Pediatric

    Secondary Protocol No: AALL1231

    Treatment: Chemotherapy

    Applicable Disease Sites: Lymphoma

    Therapies Involved: Radiation: Radiation Therapy Other: Laboratory Biomarker Analysis Drug: Steroids Drug: Chemotherapy (multiple) ID: NCT02112916

  • Objective

    This trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients

  • Key Eligibility

    Ages Eligible for Study: 2 Years to 30 Years; Genders Eligible for Study: Both; Accepts Healthy Volunteers: No